154.69 0.00 (0.00%)
After hours: 4:28PM EDT
|Bid||155.52 x 900|
|Ask||155.39 x 900|
|Day's Range||150.53 - 156.07|
|52 Week Range||110.84 - 167.35|
|Beta (3Y Monthly)||0.96|
|PE Ratio (TTM)||859.39|
|Earnings Date||Aug 7, 2017 - Aug 11, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||160.71|
Despite facing adverse foreign exchange volatility across its international business, Integra LifeSciences (IART) can successfully eye certain key developments on foreign shores.
Penumbra stock climbed above key moving averages on Tuesday, as the maker of medical devices was selected as the IBD Stock of The Day. Its products serve neurosurgical and vascular markets.
Haemonetics' (HAE) Plasma arm steadily witnesses solid growth in the fiscal third quarter on 16% revenue rise at constant currency.
ResMed's (RMD) Brightree suite upgrade will help uplift business operations by easily meeting compliance needs and offering the best quality patient care.
The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put in. But in contrast you can make muchRead More...
The deal between ResMed's (RMD) MatrixCare and PharMerica covers NCPDP (National Council for Prescription Drug Programs) Bidirectional ePrescribing with all MatrixCare customer facilities.
ALAMEDA, Calif. , Feb. 26, 2019 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the fourth quarter and full ...
NEW YORK, NY / ACCESSWIRE / February 26, 2019 / Penumbra, Inc. (NYSE: PEN ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on February 26, 2019 at 4:30 PM Eastern ...
Quest Diagnostics' (DGX) progress in prescription drug monitoring, QuantiFERON and non-invasive prenatal screening are part of its recent major developments.